Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryMar 14, 2022	Agile Therapeutics Announces Closing of $4.85 Million Registered Direct Offering PRINCETON, N.J., March 14, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced that it has closed its previously announced registered direct offering with a single healthcare-focused institutional...	PDF Version
Toggle SummaryMay 25, 2023	Agile Therapeutics Announces Closing of $7.5 Million Public Offering PRINCETON, N.J., May 25, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced the closing of its previously announced public offering of an aggregate of 1,896,286 shares of its common stock (or...	PDF Version
Toggle SummaryJan 2, 2012	Agile Therapeutics Announces Completion of AG200-15 Phase III Clinical Program
Toggle SummaryOct 19, 2015	Agile Therapeutics Announces Completion of Patient Enrollment in Twirla(R) Phase 3 SECURE Clinical Trial Company Plans to Complete Clinical Trial in the Second Half of 2016 and File its Resubmission to the FDA in First Half of 2017...	Agile Therapeutics Announces Completion of Patient Enrollment in Twirla(R) Phase 3 SECURE Clinical Trial 19.2 KB
Toggle SummaryAug 31, 2015	Agile Therapeutics Announces Completion of Patient Recruitment in Twirla(R) Phase 3 SECURE Clinical Trial Company on Track to Complete Study Enrollment for Its Combined Hormonal Contraceptive Patch by the End of Third Quarter 2015...	Agile Therapeutics Announces Completion of Patient Recruitment in Twirla(R) Phase 3 SECURE Clinical Trial 18.9 KB
Toggle SummaryMar 25, 2024	Agile Therapeutics Announces Delisting from Nasdaq PRINCETON, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women's healthcare company, today announced that the Company has received a final delisting notice from Nasdaq. The delisting is a result of failure to regain...	PDF Version
Toggle SummaryJan 26, 2023	Agile Therapeutics Announces Distribution of Series C Preferred Stock to its Holders of Common Stock PRINCETON, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock, par value $0.0001 per share, for...	PDF Version
Toggle SummaryFeb 22, 2024	Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds PRINCETON, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women's healthcare company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an...	PDF Version
Toggle SummaryFeb 15, 2024	Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement & Provides Performance Update Company Granted Extension by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement Until March 25, 2024 Net Revenue for Full Year 2023 Expected to be in the Range of $20 to $21 Million, an Increase of 84% to 93% Compared to Full Year 2022 GAAP...	PDF Version
Toggle SummaryOct 30, 2019	Agile Therapeutics Announces Favorable Outcome of FDA Advisory Committee Meeting for its Investigational Transdermal Contraceptive Patch, Twirla® (AG200-15) Committee Votes 14 to 1, with 1 Abstention, in Favor of Approval PRINCETON, N.J. , Oct. 30, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, announced a positive outcome from today’s meeting of the Bone, Reproductive and Urologic Drugs Advisory...	PDF Version